恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 07-11 16:08:03

72.200

-2.350

-3.15%

最高78.750	最低71.500	成交量782.78万
今开72.500	昨收74.550	日振幅9.73%
总市值4,792亿	流通市值186.28亿	总股本66.37亿
成交额5.81亿	换手率3.03%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":72.2,"timestamp":1752221283030,"preClose":74.55,"halted":0,"volume":7827794,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.0940992716312947,"marketStatus":"未开盘","change":-2.35,"latestTime":"07-11 16:08:03","open":72.5,"high":78.75,"low":71.5,"amount":580692063,"amplitude":0.09725,"askPrice":72.35,"askSize":400,"bidPrice":72.2,"bidSize":12600,"shortable":0,"etf":0,"ttmEps":1.1941251093416425,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752456600000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":74.55,"dividendRate":0.003031,"openAndCloseTimeList":[[1752197400000,1752206400000],[1752210000000,1752220800000]],"volumeRatio":1.3412951151629056,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":56.9,"timestamp":1752217200000,"preClose":57.6,"halted":0,"volume":65863100,"delay":0,"premium":"+15.98"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2551778914","title":"恒瑞医药：BD潜力或超300亿美元？","url":"https://stock-news.laohu8.com/highlight/detail?id=2551778914","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551778914?lang=zh_cn&edition=full","pubTime":"2025-07-13 07:03","pubTimestamp":1752361419,"startTime":"0","endTime":"0","summary":"近日创新药龙头恒瑞医药AH股价大涨，H股2日涨幅超过20%，A股也是创今年新高，目前市值逼近4000亿元关口。2023年至今，恒瑞医药已累计达成9笔对外授权BD交易，这些交易为公司带来了6.6亿美元的首付款收入，同时锁定了包含里程碑付款和销售分成在内的高达131亿美元潜在总金额。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713071123a4471264&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713071123a4471264&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1191","600276"],"gpt_icon":1},{"id":"2550199248","title":"恒瑞通取得一种能自动整理和投放纸张的智能五夹胶装机专利，提高五夹胶装机的智能性","url":"https://stock-news.laohu8.com/highlight/detail?id=2550199248","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550199248?lang=zh_cn&edition=full","pubTime":"2025-07-12 17:11","pubTimestamp":1752311519,"startTime":"0","endTime":"0","summary":"金融界2025年7月12日消息，国家知识产权局信息显示，银川恒瑞通彩色印刷有限公司取得一项名为“一种具有纸张整理机构的智能五夹胶装机”的专利，授权公告号CN223085704U，申请日期为2024年10月。通过天眼查大数据分析，银川恒瑞通彩色印刷有限公司参与招投标项目15次，财产线索方面有商标信息2条，专利信息1条，此外企业还拥有行政许可3个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712172254953fc8b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712172254953fc8b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","01276","BK1191"],"gpt_icon":0},{"id":"2550931800","title":"【关注】湖南药企猛攻化药贴膏剂，超70亿市场掀热浪","url":"https://stock-news.laohu8.com/highlight/detail?id=2550931800","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550931800?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:56","pubTimestamp":1752224160,"startTime":"0","endTime":"0","summary":"精彩内容日前，CDE官网显示，湖南华纳大药厂的艾氟洛芬贴剂临床申请获受理。米内网数据显示，化药贴膏剂在近年中国三大终端六大市场销售规模持续攀升，2024年突破70亿元，同比增长9.22%。目前，湖南华纳大药厂已有2款化药贴膏剂报产在审。从治疗大类来看，肌肉-骨骼系统的市场份额一直独秀，占比超过80%。湖南华纳大药厂化药贴膏剂报产在审产品来源：米内网中国申报进度数据库","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711174117a6a387ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711174117a6a387ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","01276","LU2148510915.USD","LU0405327494.USD","LU1969619763.USD","LU1328615791.USD","600276","BK0188","BK0012","BK0060","BK0239","LU2488822045.USD","LU1064131003.USD","LU1064130708.USD","BK0196","LU2495084118.USD","BK0028","LU1997245177.USD","LU0405327148.USD","LU1997244956.HKD","LU1997245094.SGD","LU2328871848.SGD","LU1655091616.SGD"],"gpt_icon":0},{"id":"2550910603","title":"加仓100%！全球巨头出手","url":"https://stock-news.laohu8.com/highlight/detail?id=2550910603","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550910603?lang=zh_cn&edition=full","pubTime":"2025-07-11 09:32","pubTimestamp":1752197570,"startTime":"0","endTime":"0","summary":"景顺旗舰基金加仓恒瑞医药100%美国资管巨头景顺旗下基金Invesco Developing Markets 最新持仓数据显示：5月，该基金加仓恒瑞医药幅度达100%。中国已成为全球制药和生物技术巨头寻求临床管线的重要市场。日前，新加坡国有投资机构淡马锡发布的年度财报显示，截至2025年1季度末，淡马锡组合资产净值达3400亿美元，同比增长11.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711093717a6a29ab8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711093717a6a29ab8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1116","600276","BK1191","01276"],"gpt_icon":1},{"id":"2550677014","title":"恒瑞医药 KRAS 肿瘤疫苗首次获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2550677014","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550677014?lang=zh_cn&edition=full","pubTime":"2025-07-11 08:18","pubTimestamp":1752193081,"startTime":"0","endTime":"0","summary":"7 月 9 日，CDE 官网显示，恒瑞医药旗下瑞宏迪医药和瑞领医药申报的1 类治疗用生物制品 RGL-232 注射液正式获批临床，用于治疗携带 KRAS 突变的恶性实体肿瘤。公开资料显示，这是该药首次获批临床。Insight 数据库显示，在 KRAS 疫苗领域，全球共有 11 款进入临床阶段，进展最快的是Circio Holding ASA的TG01，已经启动 II 期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083507a44375ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711083507a44375ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","600276","01276"],"gpt_icon":1},{"id":"2550628650","title":"IPO雷达｜背靠恒瑞闯港股，景泽生物负债率486%，如何趟过生物类似药红海？","url":"https://stock-news.laohu8.com/highlight/detail?id=2550628650","media":"子弹财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550628650?lang=zh_cn&edition=full","pubTime":"2025-07-10 20:16","pubTimestamp":1752149760,"startTime":"0","endTime":"0","summary":"1一年亏损2.4亿，现金仅够支撑5个月招股书显示，景泽生物作为聚焦辅助生殖药物与眼科药物两大高增长赛道的生物制药企业，在细分领域展现出显著的研发管线优势。据弗若斯特沙利文数据，截至2025年6月27日，景泽生物在辅助生殖与眼科两大治疗领域的临床阶段大分子药物布局数量，位居中国企业前列。图 / 公司招股书此次赴港上市对景泽生物而言，堪称生死攸关的战略抉择。但JZB30并不是原研药，而是粉针剂型果纳芬的生物类似药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710202959a4429c96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710202959a4429c96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","BK1191","01276","HSTECH"],"gpt_icon":1},{"id":"2550323696","title":"百度押注的医疗AI公司冲刺IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2550323696","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550323696?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:45","pubTimestamp":1752115500,"startTime":"0","endTime":"0","summary":"与此同时，近期又有一家专注于医疗AI的公司正在冲击港股IPO。01 专注于AI全病程管理服务，百度、IDG押注微脉的总部位于浙江杭州，其历史可以追溯至2013年，当时微脉技术注册成立，目前是公司的主要营运实体之一。03 面临京东健康、平安好医生等巨头的竞争，微脉的市场份额为0.71%今年以来，创新药和医疗AI是医药行业最受关注的子领域，微脉正处于医疗AI这一分支。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710105424a4418945&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710105424a4418945&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIDU","89888","01276","BK1191","09888","600276"],"gpt_icon":1},{"id":"1185498593","title":"恒瑞医药再涨6%，股价再创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1185498593","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185498593?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:52","pubTimestamp":1752112326,"startTime":"0","endTime":"0","summary":"7月10日（周四），恒瑞医药再涨6%，截止收稿，报74港元，股价再创历史新高。","market":"us","thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2550631705","title":"刚刚，杀出个医药大白马，超越恒瑞医药！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550631705","media":"飞鲸投研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550631705?lang=zh_cn&edition=full","pubTime":"2025-07-09 18:46","pubTimestamp":1752057976,"startTime":"0","endTime":"0","summary":"此消彼长科伦药业主要有输液、原料药和创新药三项业务。2025年一季度，公司输液产品持续受到集采冲击，价格压力较大，从而导致该业务整体业绩表现延续了2024年的下滑趋势。并且，科伦药业身上马太效应有望凸显，强者恒强。截至2024年年底，科伦药业直接以及通过科伦国际合计持有石四药集团20.4%股权。截至2025年一季度末，科伦药业还持有辰欣药业10.01%的股权。2022年，科伦博泰与默沙东先后达成3笔BD交易，交易合计总金额已经超过118亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709185759a69f49ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709185759a69f49ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01276","09939","BK1515","BK1161","BK1574"],"gpt_icon":1},{"id":"1114088815","title":"港股突发！两大“超巨”杀疯，股价皆创新高，究竟发生了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=1114088815","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114088815?lang=zh_cn&edition=full","pubTime":"2025-07-09 17:28","pubTimestamp":1752053305,"startTime":"0","endTime":"0","summary":"港股市场两大“超巨”暴涨！此外，在港股上市的蓝思科技、FORTIOR，大众口腔等亦迎来暴涨。两大“超巨”杀疯今天，市场整体上较为平淡，港股市场更是出现了明显调整，但宁德时代和恒瑞医药两大行业龙头却大幅飙涨。宁德时代H股一度狂飙超8%，其认购证最大涨幅超过60%，并带动宁德时代A股大幅飙升。截至，今天恒瑞医药H股的最高价为71.15港元/股，离目标价还有很大空间。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港股突发！两大“超巨”杀疯，股价皆创新高，究竟发生了什么？","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","03750"],"gpt_icon":1},{"id":"2550741680","title":"恒瑞医药，反转！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550741680","media":"ARK投研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550741680?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:59","pubTimestamp":1752051542,"startTime":"0","endTime":"0","summary":"2024 年恒瑞医药创新药销售收入同比增长30%，值得注意的是，恒瑞创新药收入占比首次超过50%。作为创新药的绝对龙头，恒瑞医药今天的表现也十分强势，涨幅来到7.1%,总市值突破了3500亿元。值得注意的是，恒瑞在合作中始终保留了药物在国内的开发和销售权益，只将海外市场的权益授权给默沙东。恒瑞医药营收 279 亿元，同比增长 22%；净利润 63 亿元，同比增长 47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709171151a43ffd27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709171151a43ffd27&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0405327148.USD","LU2148510915.USD","LU1328615791.USD","LU1997245177.USD","BK0239","LU0405327494.USD","LU1064130708.USD","LU2495084118.USD","600276","LU2328871848.SGD","LU2488822045.USD","BK0196","01276","BK0183","LU1064131003.USD","LU1655091616.SGD","BK0060","BK0188","BK0012","BK0028","LU1997245094.SGD","LU1969619763.USD","LU1997244956.HKD"],"gpt_icon":0},{"id":"2550892466","title":"【香港恒生指数收跌1.06% 巨星传奇涨超90%】香港恒生指数收跌1.06%，恒生科技指数跌1.76%。巨星传奇涨超94%，恒瑞医药涨超15%；金涌投资跌超44%，国泰君安国际跌超5%，华虹半导体跌超4%，阿里巴巴跌超3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550892466","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550892466?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:11","pubTimestamp":1752048706,"startTime":"0","endTime":"0","summary":"香港恒生指数收跌1.06%，恒生科技指数跌1.76%。巨星传奇涨超94%，恒瑞医药涨超15%；金涌投资跌超44%，国泰君安国际跌超5%，华虹半导体跌超4%，阿里巴巴跌超3%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/09161151584124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["513600","02833","06683","LU0052750758.USD","BK4533","01347","LU1152091754.HKD","BK4548","LU2488822045.USD","BK1607","LU1655091616.SGD","600276","LU1328615791.USD","01276","BK4502","BK1156","LU1997244956.HKD","HSI","HSTECH","LU0072462343.USD","LU1688375341.USD","BK1614","LU1769817096.USD","LU0348816934.USD","LU0651946864.USD","MCHmain","BK4565","LU0251143458.SGD","BK0012","LU0128525689.USD","LU1051769294.HKD","BK0188","LU1969619763.USD","BK4585","BK4587","LU1769817179.HKD","LU1064131003.USD","MHImain","BK1237","LU1242518857.USD","LU0651947912.USD","BK4535","BK4538","LU1064130708.USD","ALBmain","HHImain"],"gpt_icon":0},{"id":"1139885920","title":"恒瑞医药午盘拉升涨超15%，股价创历史新高，公司SHR-2173注射液获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1139885920","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139885920?lang=zh_cn&edition=full","pubTime":"2025-07-09 13:12","pubTimestamp":1752037963,"startTime":"0","endTime":"0","summary":"7月9日（周三），恒瑞医药午盘拉升涨超15%，公司SHR-2173注射液获批临床","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2550350282","title":"【恒瑞医药港股午后拉升涨超14%】恒瑞医药港股午后拉升涨超14%，A股涨幅扩大至5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550350282","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550350282?lang=zh_cn&edition=full","pubTime":"2025-07-09 13:11","pubTimestamp":1752037882,"startTime":"0","endTime":"0","summary":"恒瑞医药港股午后拉升涨超14%，A股涨幅扩大至5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/09131151580601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0405327494.USD","LU1997245094.SGD","LU1969619763.USD","LU1064130708.USD","LU2148510915.USD","LU1997245177.USD","LU0405327148.USD","BK4614","LU1064131003.USD","BK0239","BK0012","01276","LU1328615791.USD","LU2488822045.USD","BK0028","BK0060","LU1655091616.SGD","399300","BK1191","YANG","BK0183","BK0196","LU2328871848.SGD","BK0188","LU1997244956.HKD","159982","HSTECH","LU2495084118.USD","600276"],"gpt_icon":0},{"id":"1198706611","title":"港股异动丨无惧关税威胁，港股药品股大涨，恒瑞医药涨超7%创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1198706611","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198706611?lang=zh_cn&edition=full","pubTime":"2025-07-09 10:22","pubTimestamp":1752027740,"startTime":"0","endTime":"0","summary":"港股药品股集体拉升。","market":"hk","thumbnail":"https://static.tigerbbs.com/5c06e5fd3e3d300214034b8dd188058b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5c06e5fd3e3d300214034b8dd188058b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","02186","01276"],"gpt_icon":0},{"id":"2549405305","title":"中证国寿资产ESG绿色低碳100指数上涨0.93%，前十大权重包含恒瑞医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2549405305","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549405305?lang=zh_cn&edition=full","pubTime":"2025-07-08 21:07","pubTimestamp":1751980045,"startTime":"0","endTime":"0","summary":"数据统计显示，中证国寿资产ESG绿色低碳100指数近一个月上涨2.38%，近三个月上涨10.72%，年至今上涨2.37%。据了解，中证国寿资产ESG绿色低碳100指数从沪深300指数样本中选取ESG评分、碳减排评分和绿色收入占比较高的100只上市公司证券作为指数样本，为投资者提供绿色投资基准。从中证国寿资产ESG绿色低碳100指数持仓的市场板块来看，上海证券交易所占比68.71%、深圳证券交易所占比31.29%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/08210751569393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","159717","LU1655091616.SGD","BK0060","BK0183","ESG","BK0239","LU1064131003.USD","600276","LU1997245094.SGD","399258","LU0405327148.USD","BK0012","BK0028","LU1997244956.HKD","LU2328871848.SGD","LU0405327494.USD","LU2495084118.USD","LU1969619763.USD","LU2488822045.USD","LU1064130708.USD","LU1997245177.USD","BK0188","LU2148510915.USD","01276","BK0196","LU1328615791.USD"],"gpt_icon":0},{"id":"2549610548","title":"过去十年，中国在这个领域首次超过美国","url":"https://stock-news.laohu8.com/highlight/detail?id=2549610548","media":"中国新闻周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549610548?lang=zh_cn&edition=full","pubTime":"2025-07-08 17:30","pubTimestamp":1751967015,"startTime":"0","endTime":"0","summary":"7月3日，迪哲医药公告称，舒沃哲的新药上市申请正式获得美国食品药品监督管理局批准。据方正证券统计，2025年上半年，创新药对外授权首付款已超过25亿美元，交易总金额近500亿美元，与去年全年水平几乎相仿。今年3月，阿斯利康与和铂医药达成了一项全球战略合作。截至目前，和铂医药已完成17次BD出海交易，成为中国BD出海交易最多的药企。2015—2024年首次进入临床的创新药中，中国企业原研药数量超过美国，排名第一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708173133a69cde63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708173133a69cde63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1161","BK1191","BK1574","01276","06978","BK1583"],"gpt_icon":0},{"id":"2549519632","title":"恒瑞医药(600276.SH)：HRS-9821吸入粉雾剂获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2549519632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549519632?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:19","pubTimestamp":1751962755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于HRS-9821吸入粉雾剂的《药物临床试验批准通知书》，将于近期开展临床试验。据悉，HRS-9821是小分子PDE3/PDE4 抑制剂，可有效抑制呼吸道炎症、扩张支气管，临床拟用于COPD的维持治疗。目前全球同类产品仅Ensifentrine于2024 年7月在美国获批上市，用于COPD的维持治疗。截至目前，HRS-9821相关项目累计研发投入约3,843万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK1191","BK1576","LU1997244956.HKD","LU1064131003.USD","LU2328871848.SGD","LU2148510915.USD","LU2488822045.USD","BK1141","BK0028","BK0196","600276","BK1583","BK0060","01276","LU0405327494.USD","LU1997245094.SGD","LU1655091616.SGD","BK0012","LU1064130708.USD","LU0405327148.USD","LU1997245177.USD","BK0239","LU2495084118.USD","LU1969619763.USD","03347","LU1328615791.USD","BK0188"],"gpt_icon":0},{"id":"2549510807","title":"恒瑞医药07月08日获主力加仓2537.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549510807","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549510807?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:16","pubTimestamp":1751962562,"startTime":"0","endTime":"0","summary":"07月08日, 恒瑞医药股价涨1.35%，报收60.20元，成交金额3.1亿元，换手率1.99%，振幅4.88%，量比2.42。恒瑞医药今日主力资金净流入2537.1万元，连续4日净流入，上一交易日主力净流入164.4万元。该股近5个交易日上涨11.43%，主力资金累计净流入5488.5万元；近20日主力资金累计净流入3431.3万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170311a69ccd25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170311a69ccd25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1191"],"gpt_icon":0},{"id":"2549591869","title":"威海恒瑞取得中封袋用打孔装置专利 便于对打孔器的内部进行清理","url":"https://stock-news.laohu8.com/highlight/detail?id=2549591869","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549591869?lang=zh_cn&edition=full","pubTime":"2025-07-08 12:12","pubTimestamp":1751947930,"startTime":"0","endTime":"0","summary":"本实用新型通过设置气缸、移动板和推料杆，便于对打孔器的内部进行清理，从而使得打孔器稳定地进行工作。通过天眼查大数据分析，威海恒瑞新型包装材料有限公司共对外投资了4家企业，参与招投标项目8次，财产线索方面有商标信息13条，专利信息57条，此外企业还拥有行政许可21个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122605953a5f29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122605953a5f29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.2196},{"period":"1month","weight":0.2384},{"period":"3month","weight":0.639},{"period":"ytd","weight":0.639}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":-0.0093},{"period":"3month","weight":0.1542},{"period":"6month","weight":0.2662},{"period":"1year","weight":0.3537},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}